Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus subcutaneous low-dose prednisolone in inflammatory rheumatic disease
NL-OMON49468Not yet recruiting
- Sponsor
- Reade
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of prednisolone in polymyalgia rheumatica (PMR), rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (2 arms), sponsored by Reade. Primary endpoint: Erythrocyte sedimentation rate. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
prednisolone
03
Conditions
polymyalgia rheumatica (PMR)rheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON49468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49468.